Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma

Polycomb repressive complex 2 (PRC2) components, EZH2 and its homolog EZH1, and PI3K/Akt signaling pathway are focal points as therapeutic targets for multiple myeloma. However, the exact crosstalk between their downstream targets remains unclear. We herein elucidated some epigenetic interactions fo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Rizk, Mohamed, Rizq, Ola, Oshima, Motohiko, Nakajima‐Takagi, Yaeko, Koide, Shuhei, Saraya, Atsunori, Isshiki, Yusuke, Chiba, Tetsuhiro, Yamazaki, Satoshi, Ma, Anqi, Jin, Jian, Iwama, Atsushi, Mimura, Naoya
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6890440/
https://ncbi.nlm.nih.gov/pubmed/31571328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14207
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars